Scarica l'app Stockscreener
18.55
0.38%
-0.07
Dopo l'orario di chiusura:
18.55
Precedente Chiudi:
$18.62
Aprire:
$18.94
Volume 24 ore:
653.99K
Relative Volume:
1.25
Capitalizzazione di mercato:
$1.39B
Reddito:
$62.71M
Utile/perdita netta:
$-112.51M
Rapporto P/E:
-12.28
EPS:
-1.51
Flusso di cassa netto:
$-96.01M
1 W Prestazione:
+9.63%
1M Prestazione:
+17.11%
6M Prestazione:
+64.89%
1 anno Prestazione:
+37.41%
Intervallo 1D:
$18.30
$19.37
Intervallo di 1 settimana:
$17.27
$19.50
Portata 52W:
$9.03
$19.50
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
18.55 | 1.38B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 - GlobeNewswire
What the charts say about Zymeworks Inc. todayJuly 2025 Volume & Community Consensus Stock Picks - newser.com
JPM places Zymeworks on positive catalyst watch ahead of ZW191 Phase 1 data - Investing.com
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to Trade - Yahoo Finance
JPMorgan Chase & Co. Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock Price - MarketBeat
What is HC Wainwright's Forecast for Zymeworks Q3 Earnings? - MarketBeat
Zymeworks to Announce Q3 2025 Financial Results and Host Conference Call - TipRanks
Zymeworks Inc. to Report Q3 2025 Financial Results and Host Conference Call on November 6, 2025 - Quiver Quantitative
Applying Elliott Wave Theory to Zymeworks Inc.Gold Moves & AI Enhanced Trading Alerts - newser.com
Zymeworks, Inc. Hits New 52-Week High of USD 19.50 - Markets Mojo
Will Zymeworks Inc. stock attract ESG investors2025 Earnings Surprises & Safe Entry Momentum Tips - newser.com
Zymeworks (NASDAQ:ZYME) Shares Gap UpHere's Why - MarketBeat
Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
HC Wainwright & Co. Upgrades Zymeworks (ZYME) - Nasdaq
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Will Zymeworks Inc. stock sustain high P E ratios2025 Market Outlook & AI Driven Stock Movement Reports - newser.com
How Zymeworks Inc. stock compares to market leadersJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - newser.com
Will Zymeworks Inc. stock outperform growth indexesQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Zymeworks to present early data on ZW191 cancer drug at conference - Investing.com Nigeria
Zymeworks to present early data on ZW191 cancer drug at conference By Investing.com - Investing.com South Africa
Zymeworks Presents Preliminary Phase 1 Results for ZW191 Targeting Advanced Solid Tumors at AACR-NCI-EORTC Conference - Quiver Quantitative
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference - The Manila Times
Zymeworks to Present Clinical Data from the Phase 1 trial - GlobeNewswire
Phase 1 preliminary data: ZW191 (FRα-targeting ADC) — Zymeworks to present at AACR Oct 23 - Stock Titan
Using economic indicators to assess Zymeworks Inc. potentialOptions Play & Community Consensus Picks - newser.com
What technical models suggest about Zymeworks Inc.’s comebackQuarterly Performance Summary & Precise Swing Trade Alerts - newser.com
Zymeworks (ZYME): Evaluating Valuation Following New Leadership and Key Regulatory Wins - Sahm
Is Zymeworks Inc. showing signs of accumulationForecast Cut & Short-Term Trading Alerts - newser.com
Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy? - Yahoo
Zymeworks (NYSE:ZYME) Stock Price Up 7.2%Here's What Happened - MarketBeat
Zymeworks (NASDAQ:ZYME) Reaches New 52-Week HighHere's Why - MarketBeat
Zymeworks stock hits 52-week high at 17.71 USD By Investing.com - Investing.com Canada
How Might ZYME’s Shifting Leadership Shape Its Late-Stage Oncology Ambitions? - simplywall.st
B. Riley Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks stock hits 52-week high at 17.71 USD - Investing.com
Zymeworks (ZYME) Coverage Initiated by B. Riley Securities with 'Buy' Rating | ZYME Stock News - GuruFocus
Lifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks appoints Adam Schayowitz as acting chief development officer By Investing.com - Investing.com Nigeria
Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements - TipRanks
Zymeworks appoints Adam Schayowitz as acting chief development officer - Investing.com India
Zymeworks Inc. Appoints Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer - Quiver Quantitative
Adam Schayowitz named Acting CDO at Zymeworks to advance clinical R&D and partnerships — Oct. 9, 2025 - Stock Titan
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
How to forecast Zymeworks Inc. trends using time series2025 Dividend Review & Community Consensus Trade Alerts - newser.com
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):